Antibody therapeutic (first) - Bayer HealthCare/BioInvent International
Latest Information Update: 09 Jul 2014
At a glance
- Originator Bayer HealthCare
- Developer Bayer HealthCare; BioInvent International
- Class Antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 07 Jul 2014 Phase-I clinical trials in Undefined indication in Germany (Parenteral)